Speaker
Frank Borriello, PhD,MD
CHIEF EXECUTIVE OFFICER, ALLOPLEX BIOTHERAPEUTICS
Woburn MA01801, Massachusetts, United States
Frank Borriello, MD, PhD is the Chief Executive Officer of Alloplex Biotherapeutics Inc., a private Boston-based company he founded based on an original concept, now protect by both issued patents and trade secrets.
Dr. Borriello obtained his MD, PhD degrees at the Albert Einstein College of Medicine in NYC where he studied Class I MHC structure-function relationships. He continued training at the Brigham and Women’s Hospital in Boston with a residency in clinical pathology and a laboratory research focus in cellular immunology and the B7-CD28 costimulatory pathway.
He has an extensive 20+ year background in the biotech/pharma industry spanning diverse roles such as clinical development (Wyeth), financial buy-side analyst (BB Biotech) and Business Development with Millennium, Takeda, Shire and finally at Baxalta as VP of Search and Evaluation until its acquisition in 2016.
In 2016, he conceived of a novel differentiated, non-engineered approach to immuno-oncology (now called ‘SUPLEXA’) and established Alloplex Biotherapeutics to reduce the concept to practice.
As Scientific Founder and CEO of Alloplex, Dr. Borriello has led the organization through research, fundraising and business development, and into first-in-human clinical trials for the lead SUPLEXA cell therapy program which is currently underway in Australia.
SUPLEXA is a potential first-in-class, individualized, pan cancer-cellular therapy comprised of a mixture of cells with well-understood anti-tumor activity including NK, NK-T and T cells.
Dr. Borriello obtained his MD, PhD degrees at the Albert Einstein College of Medicine in NYC where he studied Class I MHC structure-function relationships. He continued training at the Brigham and Women’s Hospital in Boston with a residency in clinical pathology and a laboratory research focus in cellular immunology and the B7-CD28 costimulatory pathway.
He has an extensive 20+ year background in the biotech/pharma industry spanning diverse roles such as clinical development (Wyeth), financial buy-side analyst (BB Biotech) and Business Development with Millennium, Takeda, Shire and finally at Baxalta as VP of Search and Evaluation until its acquisition in 2016.
In 2016, he conceived of a novel differentiated, non-engineered approach to immuno-oncology (now called ‘SUPLEXA’) and established Alloplex Biotherapeutics to reduce the concept to practice.
As Scientific Founder and CEO of Alloplex, Dr. Borriello has led the organization through research, fundraising and business development, and into first-in-human clinical trials for the lead SUPLEXA cell therapy program which is currently underway in Australia.
SUPLEXA is a potential first-in-class, individualized, pan cancer-cellular therapy comprised of a mixture of cells with well-understood anti-tumor activity including NK, NK-T and T cells.
Speaking In
4:15 PM - 5:15 PM
Wednesday, June 7
